X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XFOR X4 Pharmaceuticals Inc

Not Yet Opened 11-26 16:00:00 EST

0.3523

+0.0167

+4.98%

盘后0.3400

-0.0123-3.49%

19:58 EST

High0.3588	Low0.3333	Vol1.20M
Open0.3336	D1 Closing0.3356	Amplitude7.60%
Mkt Cap60.08M	Tradable Cap45.77M	Total Shares170.55M
T/O415.84K	T/O Rate0.93%	Tradable Shares129.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4 Pharmaceuticals Inc","latestPrice":0.3523,"timestamp":1732654800000,"preClose":0.3356,"halted":0,"volume":1204299,"hourTrading":{"tag":"盘后","latestPrice":0.34,"preClose":0.3523,"latestTime":"19:58 EST","volume":32352,"amount":11295.8291,"timestamp":1732669133248},"delay":0,"floatShares":129912749,"shares":170546469,"eps":-0.085969,"marketStatus":"Not Yet Opened","change":0.0167,"latestTime":"11-26 16:00:00 EST","open":0.3336,"high":0.3588,"low":0.3333,"amount":415836.35181072,"amplitude":0.075983,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.085969,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732698000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":0.3356,"preHourTrading":{"tag":"盘前","latestPrice":0.3356,"preClose":0.3356,"latestTime":"09:25 EST","volume":43273,"amount":14815.4981744,"timestamp":1732631150586},"postHourTrading":{"tag":"盘后","latestPrice":0.34,"preClose":0.3523,"latestTime":"19:58 EST","volume":32352,"amount":11295.8291,"timestamp":1732669133248},"volumeRatio":0.442075,"impliedVol":0.7705,"impliedVolPercentile":0.2372},"requestUrl":"/m/hq/s/XFOR/tweets","defaultTab":"tweets","newsList":[{"id":"2485127471","title":"Spotlight On 3 US Penny Stocks With At Least $60M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2485127471","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485127471?lang=en_us&edition=fundamental","pubTime":"2024-11-21 04:05","pubTimestamp":1732133102,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences fluctuations ahead of major earnings reports, investors are keenly observing opportunities across various sectors. Penny stocks, a term that may seem outdated, still represent an intriguing segment for those interested in smaller or newer companies. By focusing on penny stocks with solid financial foundations and growth potential, investors can find opportunities that offer both value and stability amidst current market conditions.Overview: X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics for rare diseases, with a market cap of $62.76 million.Overview: Acacia Research Corporation specializes in acquiring and managing companies within the technology, energy, and industrial sectors, with a market cap of $430.37 million.Acacia Research Corporation, with a market cap of US$430.37 m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tBaSnVjf_e_xG_Ru362rkw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/51efc4c16661a09e764445427d52ecc6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tBaSnVjf_e_xG_Ru362rkw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/51efc4c16661a09e764445427d52ecc6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spotlight-3-us-penny-stocks-200502506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4123","BK4213","BABB","BK4209","BK4164","XFOR","BK4096","PHX","SES","ACTG"],"gpt_icon":0},{"id":"2484678750","title":"B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678750","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484678750?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:01","pubTimestamp":1731938519,"startTime":"0","endTime":"0","summary":"B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RILY","XFOR"],"gpt_icon":0},{"id":"2483380460","title":"X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483380460","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483380460?lang=en_us&edition=fundamental","pubTime":"2024-11-15 02:19","pubTimestamp":1731608340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XFOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 13:19 ET (18:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR"],"gpt_icon":0},{"id":"2483533585","title":"XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…","url":"https://stock-news.laohu8.com/highlight/detail?id=2483533585","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483533585?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:29","pubTimestamp":1731590940,"startTime":"0","endTime":"0","summary":"On November 13, 2024, X4 Pharmaceuticals, Inc.  announced positive topline results from the Phase 2 trial of mavorixafor in patients with chronic neutropenia . This was a six-month, open label trial that enrolled a total of 23 participants diagnosed with either idiopathic, congenital, or cyclic CN. There were two study groups in the trial: mavorixafor monotherapy  and mavorixafor in combination with granulocyte colony-stimulating factor . The following slide give an overview of the study population.X4 is continuing participant enrollment in the Phase 3 4WARD trial of mavorixafor in CN patients with congenital, autoimmune, or idiopathic chronic neutropenia. The trial is expected to enroll 150 participants with an ANC <1500 cells/mL and a history of two or more infections requiring intervention in the last 12 months. The primary endpoint is a two-component endpoint based on a positive ANC response and annualized infection rate, with secondary endpoints evaluating severity and duration of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2V8.Q2qHrcNNO78KEWYAg--~B/aD03MDg7dz0xMjI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/76889097e3190f43ee7c8e9a1abf3cee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2V8.Q2qHrcNNO78KEWYAg--~B/aD03MDg7dz0xMjI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/76889097e3190f43ee7c8e9a1abf3cee"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xfor-positive-results-phase-2-132900509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CN","XFOR"],"gpt_icon":0},{"id":"2483284055","title":"X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483284055","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483284055?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:06","pubTimestamp":1731567988,"startTime":"0","endTime":"0","summary":"Cash and Equivalents: Ended the third quarter of 2024 with almost $136 million.Sales Strategy: Initial sales appear flat quarter over quarter due to product stocking during launch.Market Engagement: Engaged with all 3,400 targeted immunologists and hematologists for the first phase of the launch.Coverage: More than 150 million lives covered with favorable policy decisions.Phase Three Trial Enrollment: Expected full trial enrollment in mid-2025.GuruFocus has detected 5 Warning Signs with XFOR.X4 Pharmaceuticals Inc  received FDA approval for their first product, Maverick, for the treatment of WHIM syndrome, a rare primary immunodeficiency disease.X4 Pharmaceuticals Inc  ended the third quarter of 2024 with cash and equivalents of almost $136 million, providing a financial runway into late 2025.A: The choice to adjust G CSF dosing was left to the physicians and patients, based on the robust ANC responses due to the addition of Maverick. Physicians were comfortable with the level of ANC a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sR8MxIT_s7ckRNHvinvR5w--~B/aD0yODY7dz0yODY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4efdeb76dddde6d03ec7b670620e78fa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sR8MxIT_s7ckRNHvinvR5w--~B/aD0yODY7dz0yODY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4efdeb76dddde6d03ec7b670620e78fa"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/x4-pharmaceuticals-inc-xfor-q3-070628091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XFOR"],"gpt_icon":0},{"id":"2483890374","title":"X4 Pharmaceuticals Inc :  Piper Sandler Cuts Target Price to $2 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2483890374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483890374?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:34","pubTimestamp":1731558892,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3MK2VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483988880","title":"X4 Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483988880","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483988880?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:27","pubTimestamp":1731511676,"startTime":"0","endTime":"0","summary":"* X4 Pharmaceuticals Inc    reported a quarterly adjusted loss of 18 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -1 cent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR"],"gpt_icon":0},{"id":"2483057004","title":"BRIEF-X4 Pharmaceuticals Reports Q3 2024 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483057004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483057004?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:52","pubTimestamp":1731502331,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Reports Q3 2024 Financial Results AndProvides Corporate UpdateNov 13  - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEX4 PHARMACEUTICALS: CO HAD $135.8 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH, & SHORT-TERM MARKETABLE SECURITIES AS OF SEPT 30, 2024Source text: nGNX5FQyZ8Further company coverage: XFOR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUABHNKKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":1},{"id":"2483001793","title":"BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483001793?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:38","pubTimestamp":1731501514,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor Nov 13  - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COMPLETED SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN ABSOLUTE NEUTROPHIL COUNTSX4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN G-CSF DOSING WHILE MAINTAINING ANCX4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTSSource text: nGNX9zwzFhFurther company coverage: XFOR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483003748","title":"X4 Pharmaceuticals: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483003748","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483003748?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:13","pubTimestamp":1731496433,"startTime":"0","endTime":"0","summary":"BOSTON  — BOSTON  — X4 Pharmaceuticals, Inc.  on Wednesday reported a loss of $36.7 million in its third quarter.On a per-share basis, the Boston-based company said it had a loss of 18 cents.The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.The company posted revenue of $560,000 in the period, which also fell short of Street forecasts. Six analysts surveyed by Zacks expected $1.8 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/x4-pharmaceuticals-q3-earnings-snapshot-111353693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XFOR"],"gpt_icon":0},{"id":"2483070817","title":"X4 Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $560.00K Miss $1.69M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483070817","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483070817?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:10","pubTimestamp":1731496203,"startTime":"0","endTime":"0","summary":"X4 had $135.8 million in cash, cash equivalents, restricted cash, and short-term marketable securities as of September 30, 2024. The Company believes it has sufficient funds to support operations into late 2025 and notes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41933617/x4-pharmaceuticals-q3-2024-gaap-eps-0-18-misses-0-17-estimate-sales-560-00k-miss-1-69m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"X4 Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $560.00K Miss $1.69M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR"],"gpt_icon":0},{"id":"2483077275","title":"X4 Pharmaceuticals Q3 Operating Expenses USD 35.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077275","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077275?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXABF078:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2483077274","title":"X4 Pharmaceuticals Q3 EPS USD -0.18 VS. Ibes Estimate USD -0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077274?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXABF078:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2483701030","title":"X4 Pharmaceuticals: Co Had $135.8 Mln in Cash, Cash Equivalents, Restricted Cash, & Short-Term Marketable Securities as of Sept 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483701030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483701030?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUABHNKKV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483077271","title":"X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077271?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUABHNKKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483407769","title":"X4 Pharmaceuticals Inc - Mavorixafor Well Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2483407769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483407769?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:01","pubTimestamp":1731495660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2483077659","title":"X4 Pharmaceuticals- Mavorixafor Durably Elevates Mean Absolute Neutrophil Counts","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077659?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:01","pubTimestamp":1731495660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2483077528","title":"X4 Pharmaceuticals Inc - Mavorixafor Enables Reductions in G-Csf Dosing While Maintaining Anc","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077528?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:01","pubTimestamp":1731495660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2483077524","title":"X4 Pharmaceuticals Announces Positive Results From Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077524?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:01","pubTimestamp":1731495660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2483070820","title":"X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483070820","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483070820?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:01","pubTimestamp":1731495660,"startTime":"0","endTime":"0","summary":"Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts . Mavorixafor enabled substantial reductions in G-CSF dosing while maintainingmean ANC at normal levels. Phase 2 study results and new analysis confirming functionality of neutrophils in sub-study participants bolster confidence in achieving success in Phase 3 4WARD trial. Results from Completed Phase 2 Study of Mavorixafor in CNThe Phase 2 study of mavorixafor was a six-month, open-label clinical trial that enrolled a total of 23 participants diagnosed with idiopathic, congenital, or cyclic chronic neutropenia. The analysis presented today includes results from the two study treatment groups: mavorixafor monotherapy  and mavorixafor in combination with G-CSF","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwjmAgOPVahP9tzaWgT7gw--~B/aD0xNDA7dz0yMTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f52dcd7c2b97be91e61eac10bc1f135c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwjmAgOPVahP9tzaWgT7gw--~B/aD0xNDA7dz0yMTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f52dcd7c2b97be91e61eac10bc1f135c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/x4-pharmaceuticals-announces-positive-results-110100760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","XFOR","CN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.2751},{"period":"3month","weight":-0.4894},{"period":"6month","weight":-0.639},{"period":"1year","weight":-0.5425},{"period":"ytd","weight":-0.5798}],"compareEarnings":[{"period":"1week","weight":0.0175},{"period":"1month","weight":0.0373},{"period":"3month","weight":0.0759},{"period":"6month","weight":0.1493},{"period":"1year","weight":0.3216},{"period":"ytd","weight":0.2637}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.003431},{"month":2,"riseRate":0.714286,"avgChangeRate":0.081966},{"month":3,"riseRate":0.571429,"avgChangeRate":0.137927},{"month":4,"riseRate":0.285714,"avgChangeRate":0.026234},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.016456},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.244326},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.029016},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.090685},{"month":9,"riseRate":0.285714,"avgChangeRate":0.011165},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.121911},{"month":11,"riseRate":0.285714,"avgChangeRate":0.186881},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.202177}],"exchange":"NASDAQ","name":"X4 Pharmaceuticals Inc","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"X4 Pharmaceuticals Inc,XFOR,X4 Pharmaceuticals Inc股票,X4 Pharmaceuticals Inc股票老虎,X4 Pharmaceuticals Inc股票老虎国际,X4 Pharmaceuticals Inc行情,X4 Pharmaceuticals Inc股票行情,X4 Pharmaceuticals Inc股价,X4 Pharmaceuticals Inc股市,X4 Pharmaceuticals Inc股票价格,X4 Pharmaceuticals Inc股票交易,X4 Pharmaceuticals Inc股票购买,X4 Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction